EU approves Novartis drug Signifor for Cushing's disease

European Union regulators have given Swiss pharmaceutical group Novartis a green light to market its drug Signifor as a treatment for Cushing's disease, the company said Wednesday.

The group said it was the first time the EU has approved a drug to treat the , which is caused by a tumour or growth on the pituitary gland and is generally treated surgically.

"The European Commission has approved Signifor (pasireotide) for the treatment of with Cushing's disease for whom surgery is not an option or for whom surgery has failed," Novartis said in a statement.

Cushing's disease causes fatigue, depression, , upper-body obesity and a reddened moon face.

The approval follows phase-three clinical trials that found Cushing's patients who received two daily injections of Signifor for six months had reduced levels of cortisol, a stress hormone present in above-normal quantities in people with the disease.

Cushing's affects between one and two people per million each year.

Analysts at Zurich state-owned bank ZKB estimated 20,000 European patients could be treated with Signifor, generating potential sales of some $700 million (529.3 million euros) for Novartis over five years.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Supercomputers link proteins to drug side effects

19 hours ago

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments